Gooding WE - Search Results

1

Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer.

Bauman JE, Ohr J, Gooding WE, Ferris RL, Duvvuri U, Kim S, Johnson JT, Soloff AC, Wallweber G, Winslow J, Gaither-Davis A, Grandis JR, Stabile LP. Bauman JE, et al. Among authors: gooding we. Cancers (Basel). 2020 Jun 11;12(6):1537. doi: 10.3390/cancers12061537. Cancers (Basel). 2020. PMID: 32545260 Free PMC article.

2

Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck.

Vlock DR, Johnson J, Myers E, Day R, Gooding WE, Whiteside T, Pelch K, Sigler B, Wagner R, Colao D, et al. Vlock DR, et al. Among authors: gooding we. Head Neck. 1991 Jan-Feb;13(1):15-21. doi: 10.1002/hed.2880130103. Head Neck. 1991. PMID: 1989925

3

Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer.

Saito T, Kuss I, Dworacki G, Gooding W, Johnson JT, Whiteside TL. Saito T, et al. Clin Cancer Res. 1999 Jun;5(6):1263-73. Clin Cancer Res. 1999. PMID: 10389908

4

Determination of intermediate biomarker expression levels by quantitative reverse transcription-polymerase chain reaction in oral mucosa of cancer patients treated with liarozole.

Zeng Q, Smith DC, Suscovich TJ, Gooding WE, Trump DL, Grandis JR. Zeng Q, et al. Among authors: gooding we. Clin Cancer Res. 2000 Jun;6(6):2245-51. Clin Cancer Res. 2000. PMID: 10873074 Clinical Trial.

5

Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.

Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Grandis JR, et al. Among authors: gooding we. Clin Cancer Res. 2000 Jul;6(7):2794-802. Clin Cancer Res. 2000. PMID: 10914726

6

The role of topical antibiotic prophylaxis in patients undergoing contaminated head and neck surgery with flap reconstruction.

Simons JP, Johnson JT, Yu VL, Vickers RM, Gooding WE, Myers EN, Pou AM, Wagner RL, Grandis JR. Simons JP, et al. Among authors: gooding we. Laryngoscope. 2001 Feb;111(2):329-35. doi: 10.1097/00005537-200102000-00026. Laryngoscope. 2001. PMID: 11210884 Clinical Trial.

7

Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck.

Lango MN, Dyer KF, Lui VW, Gooding WE, Gubish C, Siegfried JM, Grandis JR. Lango MN, et al. Among authors: gooding we. J Natl Cancer Inst. 2002 Mar 6;94(5):375-83. doi: 10.1093/jnci/94.5.375. J Natl Cancer Inst. 2002. PMID: 11880476

8

Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance.

Hoffmann TK, Dworacki G, Tsukihiro T, Meidenbauer N, Gooding W, Johnson JT, Whiteside TL. Hoffmann TK, et al. Clin Cancer Res. 2002 Aug;8(8):2553-62. Clin Cancer Res. 2002. PMID: 12171883

9

STAT3 activation abrogates growth factor dependence and contributes to head and neck squamous cell carcinoma tumor growth in vivo.

Kijima T, Niwa H, Steinman RA, Drenning SD, Gooding WE, Wentzel AL, Xi S, Grandis JR. Kijima T, et al. Among authors: gooding we. Cell Growth Differ. 2002 Aug;13(8):355-62. Cell Growth Differ. 2002. PMID: 12193474

10

Lack of toxicity of EGFR antisense gene therapy.

Zeng Q, Kanter PM, Dhir R, Gooding WE, Huang L, Grandis JR. Zeng Q, et al. Among authors: gooding we. J Exp Ther Oncol. 2002 May-Jun;2(3):174-86. doi: 10.1046/j.1359-4117.2002.01033.x. J Exp Ther Oncol. 2002. PMID: 12415634

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

248 results

Search Page